JP2018513388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513388A5 JP2018513388A5 JP2017555636A JP2017555636A JP2018513388A5 JP 2018513388 A5 JP2018513388 A5 JP 2018513388A5 JP 2017555636 A JP2017555636 A JP 2017555636A JP 2017555636 A JP2017555636 A JP 2017555636A JP 2018513388 A5 JP2018513388 A5 JP 2018513388A5
- Authority
- JP
- Japan
- Prior art keywords
- reg
- mscs
- patient
- cells
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 37
- 238000002560 therapeutic procedure Methods 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 30
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 208000027866 inflammatory disease Diseases 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 18
- 210000001616 monocyte Anatomy 0.000 claims description 16
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 230000002062 proliferating effect Effects 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 229960004641 rituximab Drugs 0.000 claims description 8
- 230000006052 T cell proliferation Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 229960004238 anakinra Drugs 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 229940090100 cimzia Drugs 0.000 claims description 2
- 229940073621 enbrel Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 229940048921 humira Drugs 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229940035567 orencia Drugs 0.000 claims description 2
- 229940116176 remicade Drugs 0.000 claims description 2
- 229940068638 simponi Drugs 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382206 | 2015-04-24 | ||
| EP15382206.9 | 2015-04-24 | ||
| PCT/EP2016/059196 WO2016170187A2 (en) | 2015-04-24 | 2016-04-25 | Biomarkers for determining the clinical response to cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513388A JP2018513388A (ja) | 2018-05-24 |
| JP2018513388A5 true JP2018513388A5 (enExample) | 2019-05-30 |
| JP6811724B2 JP6811724B2 (ja) | 2021-01-13 |
Family
ID=53015749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555636A Active JP6811724B2 (ja) | 2015-04-24 | 2016-04-25 | 細胞療法に対する臨床応答を決定するためのバイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10746729B2 (enExample) |
| EP (1) | EP3286562B1 (enExample) |
| JP (1) | JP6811724B2 (enExample) |
| CA (1) | CA2983950A1 (enExample) |
| HK (1) | HK1250176A1 (enExample) |
| IL (1) | IL255243B (enExample) |
| WO (1) | WO2016170187A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303534B2 (en) | 2018-06-05 | 2025-05-20 | Medipost Co., Ltd | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
| WO2020009648A1 (en) * | 2018-07-02 | 2020-01-09 | Nextcell Pharma Ab | Msc prediction algorithm |
| JP7628499B2 (ja) * | 2019-02-27 | 2025-02-10 | 武田薬品工業株式会社 | 同種異系療法のための改良された幹細胞集団 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564679C (en) * | 2004-03-22 | 2015-06-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| ES2595103T3 (es) * | 2007-10-17 | 2016-12-27 | Txcell | Células Tr1, células madre mesenquimales y usos de estas |
| US20140219921A1 (en) * | 2012-12-21 | 2014-08-07 | Rutgers, The State University Of New Jersey | Immunomodulating compositions and methods |
| ES2748825T3 (es) * | 2013-03-15 | 2020-03-18 | Tigenix S A U | Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular |
| US20160120910A1 (en) * | 2013-06-25 | 2016-05-05 | Tigenix S.A.U. | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
-
2016
- 2016-04-25 JP JP2017555636A patent/JP6811724B2/ja active Active
- 2016-04-25 EP EP16722548.1A patent/EP3286562B1/en active Active
- 2016-04-25 HK HK18109614.7A patent/HK1250176A1/zh unknown
- 2016-04-25 WO PCT/EP2016/059196 patent/WO2016170187A2/en not_active Ceased
- 2016-04-25 CA CA2983950A patent/CA2983950A1/en active Pending
- 2016-04-25 US US15/568,563 patent/US10746729B2/en active Active
-
2017
- 2017-10-24 IL IL255243A patent/IL255243B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lurier et al. | Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing | |
| Aschenbrenner et al. | An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells | |
| Havenar-Daughton et al. | Cytokine-independent detection of antigen-specific germinal center T follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique | |
| Zheng et al. | Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β through the NF‐κB and MAPK pathways in rheumatoid arthritis | |
| Moreau et al. | Effector mechanisms of rejection | |
| Polimeno et al. | Regulatory T cells, interleukin (IL)‐6, IL‐8, V ascular endothelial growth factor (VEGF), CXC L10, CXC L11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma | |
| Peng et al. | Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure | |
| EP2460880B1 (en) | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells | |
| Van Vugt et al. | Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts | |
| Chemin et al. | EOMES‐positive CD4+ T cells are increased in PTPN22 (1858T) risk allele carriers | |
| Márquez et al. | Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis | |
| Liu et al. | Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease | |
| Kratochvill et al. | Tristetraprolin limits inflammatory cytokine production in tumor-associated macrophages in an mRNA decay–independent manner | |
| Gao et al. | Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect | |
| FitzGerald et al. | emerging evidence for critical involvement of the interleukin‐17 pathway in both psoriasis and psoriatic arthritis | |
| US11262358B2 (en) | Infiltrating immune cell proportions predict anti-TNF response in colon biopsies | |
| JP2016502400A (ja) | ＴＮＦα阻害剤に対する応答性を予測する診断法 | |
| Wu et al. | NETs‐CD44‐IL‐17A feedback loop drives Th17‐mediated inflammation in Behçet's uveitis | |
| Delmas et al. | Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40 | |
| Yin et al. | Circulating Tfh cell and subsets distribution are associated with low‐responsiveness to hepatitis B vaccination | |
| Liu et al. | Frequency of CD4+ CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy | |
| JPWO2012002011A1 (ja) | がん患者に対する免疫療法の治療効果の予測方法、ならびに該方法に用いる遺伝子セットおよびキット | |
| Hu et al. | Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy | |
| Webb et al. | Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists | |
| KR101968452B1 (ko) | 면역요법 효능의 임상적 상관물 |